Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
External validation of the BATMAN risk score in adult ICU patients receiving beta-lactam antibiotics
NL-OMON56247Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2023
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of amoxicillin, amoxicillin + clavulanate, cefotaxime, ceftazidime, cefuroxime and 3 more in Infection, sponsored by Erasmus MC. Primary endpoints: Calibration of BATMAN risk score and Discrimination of BATMAN risk score. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
amoxicillinamoxicillin + clavulanatecefotaximeceftazidimecefuroxime
03
Conditions
Infection
Beyond the preview
Go deeper on NL-OMON56247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56247.